CDEK
← All drugs Report issue

oprozomib

Small moleculeexperimental

Oprozomib is an orally active second-generation proteasome inhibitor developed by Proteolix, which was acquired by Onyx Pharmaceuticals, an Amgen subsidiary, in 2009. It selectively inhibits chymotrypsin-like activity of both the constitutive proteasome (PSMB5) and immunoproteasome (LMP7). — Wikipedia

Clinical trial activity

9 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
9
Phase 2
5
Phase 3
0
Phase 4
0

Earliest trial started Apr 1, 2010 (NCT01129349)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COC[C@H](NC(=O)c1cnc(C)s1)C(=O)N[C@@H](COC)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1
Mol. weight
532.62 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • onx 0912
  • onx-0912
  • onx-0912
  • oprozomib
  • oprozomib
  • oprozomib
  • oprozomib
  • oprozomib

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02939183Phase 1Jan 17, 2017Amgen
NCT02227914Phase 1/Phase 2 (Phase 2)Dec 1, 2014Amgen
NCT02244112Phase 1Aug 1, 2014Amgen
NCT02072863Phase 1/Phase 2 (Phase 2)Jan 1, 2014Amgen
NCT01999335Phase 1Nov 1, 2013Amgen
NCT01881789Phase 1/Phase 2 (Phase 2)Aug 1, 2013Amgen
NCT01832727Phase 1/Phase 2 (Phase 2)May 1, 2013Amgen
NCT01416428Phase 1/Phase 2 (Phase 2)Sep 1, 2011Amgen
NCT01129349Phase 1Apr 1, 2010Amgen
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AmgenFor profit9922010
1 organizations
Page 1 / 1